Assessment of Autogenous Dentin Graft in Treatment of Infra-bony Defect

NCT05258006 | Completed

• 1 other identifier: 4
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of the present study was to evaluate the effect of demineralized autogenous dentine on treatment of infrabony defects.

Conditions

Periodontitis (Stage 3)

Outcome Measures

Primary Outcomes (4)

• Vertical bone loss

  vertical bone loss was measured from cementoenamel junction (CEJ) to the base of the bone defect in each site in group I \& II.

  6 months

• Clinical attachment level

  Clinical attachment level was measured at baseline and 6 months

  6 months

• Probing pocket depth

  Probing pocket depth was measured at baseline and 6 months

  6 months

• Bone gain

  The bone gain is calculated by: * Preoperative VBL (at baseline): measured as the distance from cementoenamel junction (CEJ) to the base of the bone defect. * Postoperative VBL (after 6 months) measured as the distance from cementoenamel junction (CEJ) to the base of the bone formation. * Postoperative bone fill (bone gain after 6 months) \[measured by subtracting the preoperative VBL from the postoperative VBL\].

  6 months

Secondary Outcomes (2)

• Plaque Index

  6 months

• Gingival index

  6 months

Study Arms (2)

Open flap debridement + allograft bone (Maxgraft)

PLACEBO COMPARATOR

Procedure: Autogenous demineralized dentin nanoparticles

Open flap debridement + Autogenous demineralized nanoparticles

ACTIVE COMPARATOR

Procedure: Autogenous demineralized dentin nanoparticles

Interventions

Autogenous demineralized dentin nanoparticles PROCEDURE

Effect of Autogenous demineralized dentin nanoparticles in bone gain in infrabony defect

Open flap debridement + Autogenous demineralized nanoparticles; Open flap debridement + allograft bone (Maxgraft)

Eligibility Criteria

• Age: 16 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients with good systemic health and no contraindication for periodontal surgery.
• Patients who are able to maintain good oral hygiene.
• Gingival thickness for the site selected should be ≥1mm.
• Probing depth of ≥ 6mm.
• Patient has at least one hopeless teeth

You may not qualify if:

• Active infectious diseases (hepatitis, tubercu¬losis, HIV, etc….).
• Medically compromised patients.
• Smokers and alcoholic abusers
• People who suffer from any systemic disease that affect the periodontium.
• Pregnant, postmenopausal women.
• People who take anti-inflammatory drugs, anti¬biotics or vitamins within the previous 3 month.
• People who use mouth washes regularly
• Participants in other clinical trials.

Sponsors & Collaborators

• October 6 University: lead

Study Sites (1)

October 6 University

Cairo, Egypt

Location

Related Publications (1)

• Elgendy EA, Elgendy AM, ElBorady OM. Clinical And Radiographic Assessment Of Autogenous Dentin Nanoparticles In Treatment Of Stage Iii Periodontitis: A Split-Mouth Clinical Study. J Pak Med Assoc. 2023 Apr;73(Suppl 4)(4):S310-S316. doi: 10.47391/JPMA.EGY-S4-60.

  PMID: 37482878 DERIVED

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal Diseases; Mouth Diseases; Stomatognathic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Periodontology

Study Record Dates

• First Submitted: February 10, 2022
• First Posted: February 25, 2022
• Study Start: January 1, 2021
• Primary Completion: November 1, 2021
• Study Completion: January 1, 2022
• Last Updated: February 25, 2022

Record last verified: 2022-02

Locations

EG (1)